InterMEL: An international biorepository and clinical database to uncover predictors of survival in early-stage melanoma
Author:
Orlow IreneORCID, Sadeghi Keimya D., Edmiston Sharon N., Kenney Jessica M., Lezcano Cecilia, Wilmott James S., Cust Anne E., Scolyer Richard A.ORCID, Mann Graham J., Lee Tim K., Burke Hazel, Jakrot Valerie, Shang Ping, Ferguson Peter M.ORCID, Boyce Tawny W., Ko Jennifer S., Ngo Peter, Funchain Pauline, Rees Judy R., O’Connell Kelli, Hao Honglin, Parrish Eloise, Conway Kathleen, Googe Paul B., Ollila David W., Moschos Stergios J., Hernando Eva, Hanniford Douglas, Argibay Diana, Amos Christopher I., Lee Jeffrey E., Osman Iman, Luo Li, Kuan Pei-FenORCID, Aurora Arshi, Gould Rothberg Bonnie E., Bosenberg Marcus W., Gerstenblith Meg R., Thompson Cheryl, Bogner Paul N., Gorlov Ivan P., Holmen Sheri L., Brunsgaard Elise K., Saenger Yvonne M., Shen Ronglai, Seshan Venkatraman, Nagore Eduardo, Ernstoff Marc S., Busam Klaus J., Begg Colin B., Thomas Nancy E., Berwick Marianne,
Abstract
Introduction
We are conducting a multicenter study to identify classifiers predictive of disease-specific survival in patients with primary melanomas. Here we delineate the unique aspects, challenges, and best practices for optimizing a study of generally small-sized pigmented tumor samples including primary melanomas of at least 1.05mm from AJTCC TNM stage IIA-IIID patients. We also evaluated tissue-derived predictors of extracted nucleic acids’ quality and success in downstream testing. This ongoing study will target 1,000 melanomas within the international InterMEL consortium.
Methods
Following a pre-established protocol, participating centers ship formalin-fixed paraffin embedded (FFPE) tissue sections to Memorial Sloan Kettering Cancer Center for the centralized handling, dermatopathology review and histology-guided coextraction of RNA and DNA. Samples are distributed for evaluation of somatic mutations using next gen sequencing (NGS) with the MSK-IMPACTTM assay, methylation-profiling (Infinium MethylationEPIC arrays), and miRNA expression (Nanostring nCounter Human v3 miRNA Expression Assay).
Results
Sufficient material was obtained for screening of miRNA expression in 683/685 (99%) eligible melanomas, methylation in 467 (68%), and somatic mutations in 560 (82%). In 446/685 (65%) cases, aliquots of RNA/DNA were sufficient for testing with all three platforms. Among samples evaluated by the time of this analysis, the mean NGS coverage was 249x, 59 (18.6%) samples had coverage below 100x, and 41/414 (10%) failed methylation QC due to low intensity probes or insufficient Meta-Mixed Interquartile (BMIQ)- and single sample (ss)- Noob normalizations. Six of 683 RNAs (1%) failed Nanostring QC due to the low proportion of probes above the minimum threshold. Age of the FFPE tissue blocks (p<0.001) and time elapsed from sectioning to co-extraction (p = 0.002) were associated with methylation screening failures. Melanin reduced the ability to amplify fragments of 200bp or greater (absent/lightly pigmented vs heavily pigmented, p<0.003). Conversely, heavily pigmented tumors rendered greater amounts of RNA (p<0.001), and of RNA above 200 nucleotides (p<0.001).
Conclusion
Our experience with many archival tissues demonstrates that with careful management of tissue processing and quality control it is possible to conduct multi-omic studies in a complex multi-institutional setting for investigations involving minute quantities of FFPE tumors, as in studies of early-stage melanoma. The study describes, for the first time, the optimal strategy for obtaining archival and limited tumor tissue, the characteristics of the nucleic acids co-extracted from a unique cell lysate, and success rate in downstream applications. In addition, our findings provide an estimate of the anticipated attrition that will guide other large multicenter research and consortia.
Funder
Foundation for the National Institutes of Health Australian Research Council Faculty of Medicine and Health, University of Sydney the Huntsman Foundation Char and Chuck Fowler Family Foundation Cleveland Foundation Roswell Park Alliance Foundation, Roswell Park Cancer Institute University of Texas MD Anderson Cancer Center Miriam and Jim Mulva Research Fund The McCarthy Skin Cancer Research Fund The Marit Peterson Fund for Melanoma Research The Irving and Nadine Mansfield and Robert David Levitt Cancer Research Chair Robert E. Leet and Clara Guthrie Patterson Trust National Institute of General Medical Sciences Cycle for Survival Marie-Josée and Henry R. Kravis Center for Molecular Oncology The Ainsworth Foundation ClearBridge Foundation The Cameron Family Melanoma Institute Australia Royal Prince Alfred Hospital
Publisher
Public Library of Science (PLoS)
Subject
Multidisciplinary
Reference28 articles.
1. Cancer statistics, 2022.;RL Siegel;CA Cancer J Clin.,2022 2. Howlader N, Noone A, Krapcho M, Garshell J, Neyman N, Altekruse S, et al. SEER Cancer Statistics Review Bethesda, MD: National Cancer Institute; 1975–2010 [updated April 2013. Available from: http://seer.cancer.gov/csr/1975_2010/]. 3. Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC Melanoma Database;SJ Soong;Ann Surg Oncol,2010 4. Malignant melanoma in the elderly: different regional disease and poorer prognosis;JB Macdonald;J Cancer,2011 5. Malignant melanoma: clinical variants and prognostic indicators;RM MacKie;Clin Exp Dermatol,2000
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|